Product Information
IRBESARTAN 75 MG TABLET is a generic product labeled by Jubilant Cadista Pharmaceuticals Inc., priced at $0.1184 per EA under NDC 59746044790. Its NADAC has been published 483 times since Dec 9, 2015.
FDA first approved this application on Feb 23, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
75 mg/1
Manufacturer
Jubilant Cadista Pharmaceuticals Inc.NDC
59746044790
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
2/19/2025
Active Ingredients
IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA203534FDA Approved
2/23/2015
TE Code
AB
On Market Since
2/24/2015
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN 75 MG TABLET has been published 483 times since Dec 9, 2015, and over the history we have for it it has declined 23.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1184 per EA |
|---|---|
| All-time high | $0.3279 (Jan 15, 2020) |
| All-time low | $0.0998 (Nov 20, 2024) |
| Median price | $0.1767 |
| Average price | $0.1771 |
| Largest weekly change | +39.1% (Dec 18, 2019) |
| Weeks tracked | 483 |
| Tracking since | Dec 9, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-16.2%
5Y
-38.5%
All
-23.6%
Last surveyed Mar 5, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 31% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Jubilant Cadista Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
IRBESARTAN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IRBESARTAN 75 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN 75 MG TABLET, manufactured by Jubilant Cadista Pharmaceuticals Inc., is $0.1184 per EA (NDC 59746044790), effective Mar 5, 2025.
How has the price of IRBESARTAN 75 MG TABLET changed over time?
Over the history we have for it, the NADAC for IRBESARTAN 75 MG TABLET has declined 23.6%. It has been tracked across 483 weekly CMS publications since Dec 9, 2015.
What are the highest and lowest recorded NADAC prices for IRBESARTAN 75 MG TABLET?
Since Dec 9, 2015, the NADAC for IRBESARTAN 75 MG TABLET has ranged from a low of $0.0998 (Nov 20, 2024) to a high of $0.3279 (Jan 15, 2020), with a median of $0.1767 per EA.
Are there cheaper alternatives to IRBESARTAN 75 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN 75 MG TABLET, is $0.0823 per EA — about 31% below IRBESARTAN 75 MG TABLET.
Who manufactures IRBESARTAN 75 MG TABLET?
IRBESARTAN 75 MG TABLET (NDC 59746044790) is labeled by Jubilant Cadista Pharmaceuticals Inc., and CMS classifies it as a generic product.